Drug safety
Vitruvias Therapeutics recalls superpotent thyroid tablets
FDA recall records say the thyroid tablets were distributed nationwide and classify the ongoing recall as Class I.
Vitruvias Therapeutics is recalling its Thyroid Tablets, USP, 1/2 Grain (30 mg), after the FDA classified the recall as Class I because the drug was superpotent. The recall is ongoing, according to FDA recall records. It started 2026-08-21 and was reported 2026-09-23.
The recalled product contains levothyroxine (T4) 19 mcg and liothyronine (T3) 4.5 mcg per tablet, and comes in bottles of 100 tablets. It is prescription-only and was distributed nationwide. FDA records list one product for recall and identify the distributor as Vitruvias Therapeutics, Auburn, AL 36830. The label says it is a product of the USA. The product's NDC is 69680-166-00.
